Evidence map›Paper›PMID 25954049›Full record

ArticleThe Journal of infectious diseases2015

High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV Infection.

Daniel C Beachler, Yingshi Guo, Wiehong Xiao, Robert D Burk, Howard Minkoff, Howard D Strickler, Ross D Cranston, Dorothy J Wiley, Lisa P Jacobson, Kathleen M Weber and 5 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. HPV-16 in a distinct subset of oral epithelial dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Daniel C BeachlerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda.
Yingshi GuoViral Oncology Program, Ohio State University Comprehensive Cancer Center, Columbus.
Wiehong XiaoViral Oncology Program, Ohio State University Comprehensive Cancer Center, Columbus.
Robert D BurkDepartment of Pediatrics Department of Microbiology and Immunology Department of Obstetrics, Gynecology, and Women's Health.
Howard MinkoffDepartment of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, New York.
Howard D StricklerDepartment of Epidemiology Department of Population Health, Albert Einstein College of Medicine, Bronx.
Ross D CranstonDepartment of Medicine, University of Pittsburgh, Pennsylvania.
Dorothy J WileySchool of Nursing, University of California-Los Angeles.
Lisa P JacobsonDepartment of Epidemiology.
Kathleen M WeberHektoen Institute of Medicine, The CORE Center at John H. Stroger Jr. Hospital of Cook County.
Joseph B MargolickViral Oncology Program, Ohio State University Comprehensive Cancer Center, Columbus.
Elizabeth A SugarDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Susheel ReddyDepartment of Infectious Disease, Northwestern University, Chicago, Illinois.
Maura L GillisonViral Oncology Program, Ohio State University Comprehensive Cancer Center, Columbus.
Gypsyamber D'SouzaDepartment of Epidemiology.
The Ohio State University · USAlbert Einstein College of Medicine · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USMaimonides Medical Center · USNational Institutes of Health · USNorthwestern University · USUniversity of California, Los Angeles · USUniversity of Pittsburgh · USWomen's Health Research Institute · CA

Funding

University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
MULTICENTER AIDS COHORT STUDYU01AI035039 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 1993 to 2018
$66.4M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
Multicenter Aids Cohort Study- Part B (Baltimore Site)U01AI035042 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BROWN, TODD T, MARGOLICK, JOSEPH B. · 1993 to 2018
$61.5M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Center for the Analysis & Management of the Multicenter AIDS Cohort StudyUM1AI035043 · NIAID · JOHNS HOPKINS UNIVERSITY · PI D'SOUZA, GYPSYAMBER, JACOBSON, LISA P · 2012 to 2018
$20.7M
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIPT32CA009314 · NCI · JOHNS HOPKINS UNIVERSITY · PI Corinne E. Joshu, Meghan Bridgid Moran · 1985 to 2026
$11.2M
Institute for Clinical and Translational ResearchUL1TR000424 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2012 to 2012
$6.0M
Effect of HIV and immunosuppression on oral HPV persistence in the HAART eraR01DE021395 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI D'SOUZA, GYPSYAMBER · 2010 to 2014
$4.3M
NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1-TR000424NCI NIH HHS T32 CA009314NCI NIH HHS T32 CA CA009314NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NIAID NIH HHS U01-AI35039NIAID NIH HHS U01-AI35041NIAID NIH HHS U01-AI35042NIAID NIH HHS UM1 AI035043NIAID NIH HHS UM1-AI35043NIDCR NIH HHS R01 DE021395PHS HHS U01-A1-35043
6 · The paper itself

Abstract

The association between oral human papillomavirus 16 (HPV16) DNA load and infection clearance was evaluated among 88 individuals with oral HPV16 infection who were identified within a prospective cohort of 1470 HIV-infected and uninfected individuals. Oral rinse specimens were collected semiannually for up to 5 years. The oral HPV16 load at the time of the first positive test result was significantly associated with the time to clearance of infection (continuous P trends <.01). Notably, clearance rates by 24 months were 41% and 94% in the highest and lowest HPV16 load tertiles (P = .03), respectively. High oral HPV16 load warrants consideration as a biomarker for infection persistence, the presumed precursor of HPV16-associated oropharyngeal cancer.

Indexed as

Viral LoadAdultAgedAged, 80 and overCohort StudiesFemaleHIV InfectionsHuman papillomavirus 16HumansMaleMiddle AgedMouth MucosaPapillomavirus InfectionsProspective StudiesTime FactorsHIVoral HPVoropharyngeal cancerpersistenceviral load

Identifiers

PMID25954049
PMCPMC4621250
OpenAlexW2247519217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.